Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation.

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Programmed death-ligand 1 (PD-L1) is a key immune checkpoint molecule overexpressed in many cancers.
• The PD-1/PD-L1 pathway is a crucial target for tumor immunotherapy, but clinical efficacy is limited.
• Understanding the regulation of PD-L1 expression is essential for improving immunotherapy outcomes.

Purpose of the Study:

• To elucidate the mechanism regulating PD-L1 protein expression.
• To investigate the role of RNF125 in PD-L1 regulation and its impact on tumor growth and immune infiltration.

Main Methods:

• Investigated the interaction between RNF125 and PD-L1.
• Assessed the effect of RNF125 on PD-L1 ubiquitination and degradation.
• Utilized RNF125 knockout and overexpression cell lines (MC-38, H22) in mouse models.
• Performed immunohistochemical analysis and analyzed The Cancer Genome Atlas (TCGA) data.

Main Results:

• RNF125 interacts with PD-L1 and promotes its K48-linked polyubiquitination and degradation.
• RNF125 knockout accelerated tumor growth and increased PD-L1 levels, while RNF125 overexpression had the opposite effect.
• RNF125 overexpression enhanced CD4+, CD8+ T cell, and macrophage infiltration in tumors.
• RNF125 expression is downregulated in human cancers, inversely correlated with clinical stage, and associated with better patient outcomes.

Conclusions:

• RNF125 acts as a negative regulator of PD-L1 expression through protein degradation.
• RNF125 promotes anti-tumor immunity by reducing PD-L1 levels and increasing immune cell infiltration.
• RNF125 represents a potential therapeutic target to enhance the efficacy of cancer immunotherapy.